| dc.contributor.author | Roland, Will | eng |
| dc.date.issued | 2017-01 | eng |
| dc.description.abstract | Since 2010 the new antimicrobials introduced have activity against resistant Gram negative bacteria, long half-lives against Gram positive bacteria, better activity against Clostridium difficile, and safer antifungal properties. Limiting factors to using the new antimicrobials include lack of susceptibility testing, cost and reimbursement issues. This article describes the new antimicrobials an internist will have contact with. | eng |
| dc.format.extent | 4 pages | eng |
| dc.identifier.uri | https://hdl.handle.net/10355/61502 | |
| dc.language | English | eng |
| dc.publisher | University of Missouri, Department of Medicine, Division of Hospital Medicine | eng |
| dc.relation.ispartof | American journal of hospital medicine, volume 1, issue 1 (2017 January-March) | eng |
| dc.rights | OpenAccess. | eng |
| dc.rights.license | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. | |
| dc.source | Harvested from the American Journal of Hospital Medicine website (http://medicine2.missouri.edu/jahm/) in 2018. | eng |
| dc.subject | resistant bacteria, Clostridium difficile, susceptibility testing, | eng |
| dc.title | New antimicrobials | eng |
| dc.type | Article | eng |
![[PDF]](/xmlui/themes/Mirage2//images/mimes/pdf.png "PDF file"){kind=small}